Zenas BioPharma, Inc. Common Stock (ZBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zenas BioPharma, Inc. Common Stock (ZBIO) has a cash flow conversion efficiency ratio of -0.232x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-57.24 Million) by net assets ($247.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Zenas BioPharma, Inc. Common Stock for the company's overall valuation and market capitalisation.
Zenas BioPharma, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Zenas BioPharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zenas BioPharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zenas BioPharma, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore ZBIO cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pan Jit International Inc
TW:2481
|
0.038x |
|
CESC Limited
NSE:CESC
|
0.120x |
|
Hunan Aihua Group Co Ltd
SHG:603989
|
0.025x |
|
LegoChem Biosciences Inc
KQ:141080
|
-0.093x |
|
YOUZU Interactive Co Ltd
SHE:002174
|
0.007x |
|
Titan Wind Energy Suzhou
SHE:002531
|
0.018x |
|
Driven Brands Holdings Inc
NASDAQ:DRVN
|
0.091x |
|
Bet Shemesh Engines Holdings 1997 Ltd
TA:BSEN
|
-0.021x |
Annual Cash Flow Conversion Efficiency for Zenas BioPharma, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Zenas BioPharma, Inc. Common Stock from 2022 to 2025. View Zenas BioPharma, Inc. Common Stock (ZBIO) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $242.14 Million | $-172.33 Million | -0.712x | -85.82% |
| 2024-12-31 | $312.46 Million | $-119.67 Million | -0.383x | -383.18% |
| 2023-12-31 | $-225.72 Million | $-30.53 Million | 0.135x | -60.39% |
| 2022-12-31 | $-192.29 Million | $-65.65 Million | 0.341x | -- |
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, an… Read more